首页|雾化吸入布地奈德联合乙酰半胱氨酸治疗新生儿呼吸窘迫综合征的临床疗效

雾化吸入布地奈德联合乙酰半胱氨酸治疗新生儿呼吸窘迫综合征的临床疗效

Clinical efficacy of nebulized budesonide combined with acetylcysteine in the treatment of neonatal respira-tory distress syndrome

扫码查看
目的:探讨雾化吸入布地奈德与乙酰半胱氨酸联合治疗新生儿呼吸窘迫综合征(NRDS)的临床疗效及其对患儿血气分析指标、炎性因子水平的影响.方法:选取赣南医学院第一附属医院 2021 年 9 月~2023 年 6 月收治的符合纳入标准的NRDS患儿 46 例,根据随机数字表法分为两组,对照组 23 例,试验组 23 例.入院后给予所有患儿经鼻持续气道正压通气,若经鼻持续气道正压通气压力≥6 cm H2O,吸入氧浓度>0.3,则予天然型肺表面活性物质替代治疗;予对照组患儿雾化吸入布地奈德进行治疗,试验组则在对照组基础上结合乙酰半胱氨酸进行治疗;两组均进行持续治疗,直至疾病稳定或患儿出现终点事件(死亡).比较两组患儿治疗 5 d后的临床疗效,治疗前与治疗 5 d后的血气分析指数、炎性因子水平以及支气管肺发育不良的发生情况和无创辅助通气时间.结果:治疗 5 d后试验组临床疗效优于对照组,差异有统计学意义(P<0.05).治疗5 d后两组酸碱度(PH)、动脉血氧分压(PaO2)较治疗前均有显著升高,且治疗后试验组显著高于对照组,差异有统计学意义(P<0.05);通过 5 d治疗,两组动脉血二氧化碳分压(PaCO2)均明显降低,且治疗 5 d后试验组显著低于对照组,差异有统计学意义(P<0.05).治疗 5 d后两组白细胞计数(WBC)、降钙素原(PCT)及C反应蛋白(CRP)水平较治疗前显著降低,差异有统计学意义(P<0.05);且治疗后试验组显著低于对照组,差异有统计学意义(P<0.05).试验组患儿无创辅助通气时间显著短于对照组,差异有统计学意义(P<0.05).两组支气管肺发育不良发生情况比较,差异无统计学意义(P>0.05).结论:布地奈德与乙酰半胱氨酸雾化吸入联合治疗NRDS的疗效确切,能显著改善患儿血气分析,同时调节炎性因子水平,缩短无创辅助通气时间,安全性较好.
Objective To explore the clinical efficacy of nebulized budesonide combined with acetylcysteine in the treatment of NRDS and its impact on blood gas analysis indicators and inflammatory cytokine levels in pediatric patients.Method According to the random number table method,NRDS patients admitted to the First Affiliated Hospital of Gannan Medical College from September 2021 to June 2023 who met the inclusion criteria were divided into two groups(a control group of 23 cases and an experimental group of 23 cases).After admission,all children were given continuous positive airway pressure ventilation through the nose.If the nasal continu-ous positive airway pressure ventilation pressure was≥6 cm H2 O and the inhaled oxygen concentration was>0.3,natural pulmonary surfactant replacement therapy was given;The control group was treated with nebulized budesonide inhalation,while the experimental group was treated with acetylcysteine in combination with the above foundation;Both groups received continuous treatment until the dis-ease stabilized or the patient experienced an endpoint event(death).Compare the clinical efficacy of two groups of pediatric patients after 5 days of treatment,including blood gas analysis index,inflammatory factor levels,incidence of bronchopulmonary dysplasia,and non-invasive assisted ventilation time before and after treatment.Results After 5 days of treatment,the clinical efficacy of the experi-mental group was more significant than that of the control group(P<0.05).After 5 days of treatment,the pH and arterial oxygen par-tial pressure of both groups significantly increased compared to before treatment,and the experimental group was significantly higher than the control group after treatment(P<0.05);After 5 days of treatment,both groups showed a significant decrease in arterial car-bon dioxide partial pressure,and after 5 days of treatment,the experimental group was significantly lower than the control group(P<0.05).After 5 days of treatment,the white blood cell count,procalcitonin and C-reactive protein levels in both groups were significantly reduced compared to before treatment(P<0.05),and the experimental group was significantly lower than the control group after treat-ment(P<0.05).The non-invasive assisted ventilation time of the experimental group was significantly shorter than that of the control group(P<0.05).There was no significant difference in the incidence of bronchopulmonary dysplasia between the two groups(P>0.05).Conclusion The combination of budesonide and acetylcysteine nebulization inhalation has a definite therapeutic effect on neo-natal respiratory distress syndrome,which can significantly improve blood gas analysis in children,regulate inflammatory factor levels,shorten non-invasive auxiliary ventilation time,and have good safety.

Neonatal respiratory distress syndromeAcetylcysteine for inhalationBudesonide suspension

杨欣、邱建平、朱小丽

展开 >

赣南医科大学第一附属医院新生儿科,江西 赣州 341000

寻乌县人民医院儿科

新生儿呼吸窘迫综合征 吸入用乙酰半胱氨酸 布地奈德混悬液

2025

吉林医学
吉林省人民医院

吉林医学

影响因子:0.926
ISSN:1004-0412
年,卷(期):2025.46(1)